Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KOMET: Selumetinib in Adult Participants With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
NCT04924608Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) comparing Arm A (Selumetinib) with Arm B (Placebo) (2 arms). Primary endpoint: Objective Response Rate at Cycle 16. Started Nov 2021; status: active, not recruiting.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT04924608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04924608.